Greuber, Emileigh
Vought, Kip
Patel, Kalpana
Suzuki, Hiroaki
Usuda, Kazuhiro
Shiramizu, Akira
Koplowitz, Luana Pesco
Koplowitz, Barry
Maibach, Howard I.
Lissin, Dmitri
Article History
Received: 14 April 2021
Accepted: 20 July 2021
First Online: 12 August 2021
Declarations
:
: Emileigh Greuber reports employment with Scilex Pharmaceuticals, Inc., during the conduct of the study and is currently with Regulatory and Strategic Development, Clinipace, Inc., Morrisville, NC, USA. Kip Vought reports employment with Scilex Pharmaceuticals, Inc., during the conduct of the study. Kalpana Patel reports employment with Scilex Pharmaceuticals, Inc., during the conduct of the study and outside the submitted work. Hiroaki Suzuki, Kazuhiro Usuda, and Akira Shiramizu report nothing to disclose. Luana Pesco Koplowitz reports receiving consultancy fees from Scilex Pharmaceuticals, Inc., during the conduct of the study. Barry Koplowitz reports receiving consultancy fees from Scilex Pharmaceuticals, Inc., during the conduct of the study. Howard I. Maibach reports receiving consultancy fees from Scilex Pharmaceuticals, Inc., as a Principal Scientist. Dmitri Lissin reports employment with Scilex Pharmaceuticals, Inc., during the conduct of the study and outside the submitted work. This article is the sole work of the authors; stated opinions or assertions do not reflect the opinions of employers or employee affiliates listed.